Categories:
![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2023/08/2023.07.31_EMA-ICH-opens-public-consultation-for-international-harmonization-of-real-world-evidence-terminology.jpg)
EMA – ICH opens public consultation for international harmonization of real-world evidence terminology
The European Medicines Agency has published for public consultation an ICH Reflection Paper on [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/03/Imagem-79.jpg)
EDQM – Notification to CEP holders: Implementation of the European Pharmacopoeia Supplement 10.7
In October 2021, the EDQM (European Directorate for the Quality of Medicines and Healthcare) [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/03/Imagem-75.jpg)
EMA – Concern on the safety of titanium dioxide could result in reformulation of drug products in Europe (updated on August 10, 2022)
Since 2020, titanium dioxide (TiO2) has been the subject of concern about its safety for use as [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2021/09/Imagem-73-1.jpg)
EMA – Update of Pre-authorisation guidance for users of the centralised procedure
In July and September, the authority EMA (European Medicines Agency) updated the document [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/03/Imagem-73.jpg)
EMA – Update of Pre-authorisation guidance for users of the centralised procedure
In July and September, the authority EMA (European Medicines Agency) updated the document [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/03/Imagem-70.jpg)
EDQM – Notification to CEP holders: Implementation of the European Pharmacopoeia Supplement 10.6
In July 2021, the EDQM (European Directorate for the Quality of Medicines and Healthcare) [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/03/Imagem-69.jpg)
EMA – Update of the Document Regulatory Q&A on Herbal Medicinal Products
In August 2021, the European Medicines Agency-EMA published an update of the regulatory [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/03/Imagem-67.jpg)
EMA – Update of the Guideline on post-authorisation procedural advice for users of the centralised procedure
In July, the European Medicines Agency (EMA) has updated its Guideline on post-authorisation [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-123-1.jpg)
Whitepaper – Differences between CADIFA (Letter of Suitability of the Active Pharmaceutical Ingredient) – ANVISA and CEP (Certificate of Suitability) – EDQM
In April 2021, the New Regulatory Framework for APIs in Brazil completed one year since its [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-112.jpg)
EMA – Review of the Question and Answer Documents for Centralized Procedure
On February 2021, the European Medicines Agency (EMA) published on its website an updated [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-113.jpg)
Whitepaper: Diffferences between CTD Brazil and UE: a look at CMC requirements
Our daily lives at Vita are full of discussions about technical and regulatory differences in [...]
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-114.jpg)
EMA publishes Questions and Answers document on Brexit
On January 1, 2021, the United Kingdom (UK) will be considered a “third country” [...]
Ler mais